BFC Planning’s abrdn Life Sciences Investors HQL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$172K Buy
9,223
+282
+3% +$5.7K 0.01% 988
2026
Q2
$179K Buy
8,941
+5,132
+135% +$90.7K 0.01% 974
2026
Q1
$62K Buy
3,809
+233
+7% +$3.89K ﹤0.01% 1263
2025
Q4
$60K Hold
3,576
– – ﹤0.01% 1294
2025
Q3
$55.5K Buy
3,576
+104
+3% +$1.42K ﹤0.01% 1147
2025
Q2
$44.5K Buy
3,472
+115
+3% +$1.42K ﹤0.01% 1173
2025
Q1
$42.6K Buy
3,357
+117
+4% +$1.58K ﹤0.01% 1166
2024
Q4
$42.5K Hold
3,240
– – ﹤0.01% 1175
2024
Q3
$48.9K Buy
+3,240
New +$49K ﹤0.01% 1108

Other funds holding HQL

BFC Planning's HQL Position: Q3 2026 in Review

BFC Planning increased its abrdn Life Sciences Investors (HQL) stake by 3.2% in Q3 2026, buying an estimated $5.7K and bringing the position to 9,223 shares worth $172K. The position accounts for 0.01% of the portfolio, ranked #988.

BFC Planning first reported a position in HQL in Q3 2024 and has held it in 9 quarters since. The position peaked at $179K in Q2 2026. 74 funds tracked by Wall St. Rank hold HQL as of Q3 2026.

  • BFC Planning held 9,223 shares of abrdn Life Sciences Investors worth $172K as of Q3 2026.
  • BFC Planning bought 282 abrdn Life Sciences Investors shares in Q3 2026, an estimated $5.7K.
  • abrdn Life Sciences Investors made up 0.01% of BFC Planning's portfolio in Q3 2026, its #988 holding.
  • BFC Planning first reported a position in abrdn Life Sciences Investors in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's abrdn Life Sciences Investors position peaked at $179K in Q2 2026.
  • 74 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.